Mengke Pharmaceutical actively announced R&D data at IDWeek 2022 to help the treatment of multidrug-resistant infections

The 2022 American Infectious Diseases Week (ID Week) was held
October 19-23, 2022 in Washington, D.
C.
, USA.
On October 22, the much-watched contizolid (CZD/MRX-1) and its prodrug CZA (MRX-4) announced the clinical efficacy and safety data
of its phase II and phase III clinical trials for skin and soft tissue infections in multiple subgroups through poster on ID Week.

The data showed that the clinical efficacy and safety of CZD/CZA were similar among various subgroups.
Demonstrated haematological-related safety advantages
compared to comparable drugs.

One of the posters is "Phase II and III Skin Infection Clinical Trials on the Efficacy and Safety of CZD and CZA in Patients with Different BMI Classifications and Sexes", which analyzed the data of four completed phase II and III skin and soft tissue infection clinical trials, and showed that the main efficacy and safety of CZD/CZA were similar in subjects with different genders and BMIs.
Further support for the ongoing Global Phase III Clinical Study of Diabetic Foot and Acute Bacterial Skin and Soft Tissue Infection to recruit participants without weight and sex restrictions
.

For any kind of treatment, the application of special populations is an important issue of
clinical concern.
Two posters analyzed and interpreted
the medication results of CZD/CZA in the subgroup of people with impaired renal function.
Data from four completed phase II and III skin and soft tissue infection clinical trials showed that the primary efficacy and safety of subjects with mild and moderate renal impairment were comparable to those with normal renal function without the need to adjust the CZD/CZA dose
.
Further analysis of the pharmacokinetic data of the clinical trial of complicated skin and soft tissue infection in CZD phase III showed that the pharmacokinetic index results of subjects with mild to moderate renal impairment were similar
to those of subjects with normal renal function.

The results also support the ongoing global Phase III clinical study of diabetic foot and acute bacterial skin and soft tissue infection to recruit impaired renal patients without the need for dose
adjustment.

In addition, a poster report reported platelet safety data from
two CZD phase II and III clinical trials of complex skin and soft tissue infections.
At 7 to 14 days of treatment, there was no decrease in mean platelet counts in participants with CZD and a decrease in mean platelet counts in linezolid subjects
, a significant difference.
Further analysis of data from a subgroup of subjects who received ≥ 11 days of treatment showed that the difference in mean platelet counts was more significant
.
Hematology safety will also be the focus of
global phase III clinical studies.

The rapid advancement and excellent clinical data not only highlight the "safe and reliable" advantages of Mengke Pharmaceutical, but also indicate the possibility
of more drugs being approved in the future.

As a new "super antibiotic" with global originality, independent property rights and international research and development, Contizolid has been approved for marketing in China in June 2021, entered the national medical insurance directory in the same year, and officially implemented
on January 1, 2022.
Global multi-center clinical trials meet international regulatory requirements, and the products have the potential to enter China, the United States, the European Union and the global market in the future, providing more optimized treatment options and stronger assistance
for more patients with multidrug-resistant bacterial infections.

About CZD

Contizolid (CZD/MRX-1) is the first Class I original new drug launched in China, which belongs to the new generation of oxazolidinone antibacterial drugs
.
At present, it is approved for complicated skin and soft tissue infections
in China.
Its antibacterial spectrum can cover positive cocci, positive bacilli, mycobacteria and fungi-like, especially against drug-resistant strains
.
Due to its special mechanism of action and structure, it is not easy to cross-resist with other types of antibacterial drugs, and it is more difficult to produce drug
resistance than similar drugs.
Contizolid and linezolid are both oxazolidinone small molecule drugs, which can be rapidly distributed to subcutaneous tissues after oral preparation administration and absorption, and at the same time have strong penetration to other tissues and wide
distribution in vivo.
Current clinical studies have confirmed that the clinical efficacy of contizolid and linezolid is comparable, but the risk of hematological toxicity and drug-drug interactions is significantly reduced
.

About CZA

CZA (MRX-4) is a water-soluble prodrug
uniquely designed and developed based on the structure of contizolid.
It has a new molecular structure and can be converted to contizolid in vivo to exert its effect
.
On the basis of satisfying oral administration, intravenous administration is added to provide more medication options
for different clinical application scenarios.
A global multicenter phase III clinical study of acute bacterial infections of diabetic foot and skin and soft tissues is underway
.